Our new immunotherapy book has been published by Springer:
I want to take a moment to acknowledge the stunning group of authors who made the book a success. I’d also like to promote our fund raising effort in memory of Holbrook Kohrt, to whom the volume is dedicated – 5% of net sales will be donated by me, on behalf of all of our authors, the the Cancer Research Institute in New York. So please consider buying the book or just the chapters you want (they can be purchased individually through the link given above.
Now, the authors:
from Arlene Sharpe and her lab (Harvard Medical School, Boston):
Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies
Parallel Costimulation of Effector and Regulatory T Cells by OX40, GITR, TNFRSF25, CD27, and CD137: Implications for Cancer Immunotherapy
NK Cell Responses in Immunotherapy: Novel Targets and Applications
Sugarcone Biotech LLC is the premier immuno-oncology strategic consulting and investment firm. Our success rate in launching, building and creating value across diverse immune oncology companies is stunning. Join founder Paul Rennert at the CRI-CIMT-EATI-AACR sponsored conference, Cancer Immunotherapy: Translating Science Into Survival, to explore ways that we can add value to your company and investments.
Paul will be onsite at the Times Square Sheraton September 16 – 19.
Email email@example.com or text/call 1-508-282-6370 to arrange a meeting.
see you in NYC -
Paul Rennert, Founder & Principal of SugarCone Biotech LLC, will be attending the joint CRI/AACR event: International Cancer Immunotherapy Conference: Translating Science into Survival 2015. SugarCone Biotech LLC is a consulting firm specializing in biotech strategy and investment.
The conference is in NYC Sept 16-19 and promises to be the key immunotherapy meeting of the fall conference season. Please reach out to connect with Paul at firstname.lastname@example.org.
Sach’s is a premier international biopartnering event, a highly focused 2-day conference spanning multiple disciplines and therapeutic modalities. Paul Rennert, Founder & Principal of SugarCone Biotech LLC, will be in attendance, to introduce novel programs and companies to interested investors, and conversely, to connect up and coming biotechs and academic spin-outs to the investment community. Please reach out to Paul during the conference using the one-on-one meeting app or via email@example.com.
We hope to see you there. Here is the conference web site:
Part of the Article Series from Nature Reviews Drug Discovery, our paper hit the press today
Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery 14, 561–584. 2015. doi:10.1038/nrd4591
by Kathleen Mahoney, Paul Rennert, Gordon Freeman.
a prepublication version is available here: nrd4591 (1)
Over 100 slides on immune checkpoint combination therapy, novel targets and drug development in immuno-oncology, created for a 3 hour workshop at ICI15 (link).
As always we work from indications to discovery and back again, keeping one eye on the rapid evolution of clinical practice in oncology and the other on novel targets and therapeutics.
on SlideShare now:
Hit the link to see the full text (PDF) of Paul Rennert’s interview by Fiona Mistri, representing ICI15. The Immune Checkpoint Conference is being held next month in Boston.
Paul Rennert SugarCone Biotech LLC
Paul Rennert, Founder & Principal of SugarCone Biotech, discusses advances in tumor antigen characterization in the current issue of Biocentury Innovations, formally SciBx. The current issue covers the Immune Checkpoint scientific and competitive landscape and related subjects, see http://www.biocentury.com/scibx/currentissue.
Paul commented on several tumor antigen papers that have set the stage for a more sophisticated understanding of the meaning and potential utility of neoantigens in cancer therapeutics, including the cellular therapeutic field (TCR, TIL) and the onco-vaccine field. These papers were recently covered in our blog as well.
We’re happy to have been able to contribute to the Biocentury story, and hope you’ll enjoy their very timely current issue.
Enumeral Biomedical Holdings, Inc (ENUM) announced today a collaboration with immunotherapy powerhouse Merck (MRK) to interrogate the tumor microenvironment in colorectal cancer tissues obtained directly from patients. The goal is to identify functional cellular responses to immuno-oncology therapies being developed by Merck.
The press release is here: http://finance.yahoo.com/news/enumeral-merck-form-collaboration-predicting-130000581.html